Lord’s Mark Biotech, a subsidiary of Lord’s Mark Industries, has launched Tinefcon, a patented medicine for treating Psoriasis in India. Tinefcon is being launched as a total solution for Psoriasis in 4 forms such as a tablet, cream, shower gel, and scalp wash. It is priced in the range of Rs. 799 – Rs. 3900. Lord’s Mark Biotech, the exclusive distribution partner, is mentoring mentors and establishing a strong social media campaign to promote the product online.
The company has invested Rs. 20 Crores in marketing and distribution in India and expects a revenue of Rs.100 crores by 2025. Tinefcon has been tested in over 500 patients across India and has shown a reduction of 66% in epidermal thickness, improved the Psoriasis Area Severity Index and downregulated the psoriatic markers gene in a 12-week clinical study. Tinefcon can be safely prescribed to all patients over 18 years old.
Commenting on the launch, Mr. Sachidanand Upadhyay, MD, Lord’s Mark Biotech, said, “We are pleased to introduce Tinefcon to the Indian market. The launch of Tinefcon is in line with our mission to enrich healthcare discourse in India. With Tinefcon, we offer a comprehensive, safe, and effective treatment of psoriasis.’’
